Dec 23, 2014
Cadwalader's Antitrust Group represented Eli Lilly and Company in connection with the U.S. antitrust clearance of its proposed $5.4 billion acquisition of Novartis Animal Health. Following an in-depth review, the Federal Trade Commission cleared the transaction under the Hart-Scott-Rodino Antitrust Improvements Act on December 19, 2014, subject to a limited divestiture. The FTC’s action clears the path for the parties to close the transaction. Partners Charles (Rick) Rule, the head of the firm's Antitrust Group and co-chair of the firm's Litigation Department, and Andrew Forman led the Cadwalader team. Associates assisting with the matter include Ngoc Hulbig, Joshua Shapiro, Christian Lorenz, William Dolan, and Jessica Michaels.
Scott Cammarn, Mark Chorazak, Jonathan Watkins,Chris Gavin, Joseph Beach, Peter Morreale
Richard Brand, Stephen Fraidin, Jonathan Watkins, James Fee
Michele Maman, Thomas Curtin, Anthony De Leo, Donny Ariel
Jeffrey Rotblat will discuss "Accumulation/Aggregation/Alternative Exit Strategies" at this event.